360 related articles for article (PubMed ID: 8017411)
1. Cefepime: a new fourth-generation cephalosporin.
Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
4. [Review of oral cephalosporins. Basis for a rational choice].
Forti IN
Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
[TBL] [Abstract][Full Text] [Related]
5. Cefepime: the next generation?
Sanders CC
Clin Infect Dis; 1993 Sep; 17(3):369-79. PubMed ID: 8218678
[TBL] [Abstract][Full Text] [Related]
6. Cefepime.
Hardin TC; Jennings TS
Pharmacotherapy; 1994; 14(6):657-68. PubMed ID: 7885968
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic use in neonatal sepsis.
Yurdakök M
Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
[TBL] [Abstract][Full Text] [Related]
8. Third-generation cephalosporins: a critical evaluation.
Barriere SL; Flaherty JF
Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
Lim VK; Halijah MY
Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
[TBL] [Abstract][Full Text] [Related]
10. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Barradell LB; Bryson HM
Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
[TBL] [Abstract][Full Text] [Related]
11. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.
Bijie H; Kulpradist S; Manalaysay M; Soebandrio A
J Chemother; 2005 Feb; 17(1):3-24. PubMed ID: 15828439
[TBL] [Abstract][Full Text] [Related]
13. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Chapman TM; Perry CM
Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
[TBL] [Abstract][Full Text] [Related]
14. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
Bell JM; Turnidge JD;
Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
[TBL] [Abstract][Full Text] [Related]
15. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
17. Cefepime.
Cunha BA; Gill MV
Med Clin North Am; 1995 Jul; 79(4):721-32. PubMed ID: 7791419
[TBL] [Abstract][Full Text] [Related]
18. Cefepime: overview of activity in vitro and in vivo.
Grassi GG; Grassi C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():87-94. PubMed ID: 8150771
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy.
Jones ME; Karlowsky JA; Draghi DC; Thornsberry C; Sahm DF; Nathwani D
Int J Antimicrob Agents; 2004 Mar; 23(3):240-6. PubMed ID: 15164964
[TBL] [Abstract][Full Text] [Related]
20. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
Corser CA; Day GJ; Humble MW
N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
